Latest Modus Therapeutics News & Updates

See the latest news and media coverage for Modus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Modus Therapeutics (Modus)

Biotechnology company developing treatments for severe medical conditions

modustx.com

Headquarters: Stockholm, Sweden
Founded year: 2011
Company type: Public company
Number of employees: 7–10
Industry: Biotechnology & Medical Research

Last updated October 14

Latest news about Modus Therapeutics (Modus)

In short: Modus published its malaria study in Nature Communications but paused its CKD trial after an adverse event.

Company announcements

October 14 Modus

Modus Therapeutics pauses sevuparin CKD study enrollment

Enrollment pauses after a SUSAR event, shifting proof-of-concept to Q1 2027 while safety is evaluated.

September 3 Modus

Modus raises SEK 7.6 million through directed share issuance

The proceeds will finance Phase IIa clinical trials for anemia and advance product manufacturing ahead of proof-of-concept data expected by early 2027.

June 18 Modus

Modus Therapeutics announces SEVUSMART manuscript preprint

The Phase Ib study evaluates sevuparin in children with severe malaria, led by Prof. Kathryn Maitland at Imperial College London.

May 28 Modus

Modus Therapeutics announces decisions from its Annual General Meeting

The AGM resolved no dividend, discharged board and MD, re-elected Viktor Drvota, elected Pernilla Sandwall and Sofi Eriksson, approved SEK110,000 fees, reappointed Ernst & Young, and authorized share issues.

Media coverage

October 14 EFN

Modus Therapeutics pauses patient recruitment after suspected serious adverse reaction

The research company Modus Therapeutics has voluntarily decided to temporarily pause recruitment in the second part of the ongoing phase 2a study with sevuparin within the company's program for...

September 13 Privata Affärer

From research to phase II: Modus Therapeutics approaches key value drivers

Modus Therapeutics has taken the step into a more clinically mature phase. With an ongoing phase II study, secured funding for the next step and a portfolio...

September 3 Dagens industri

The research company makes a new issue

The research company Modus Therapeutics has decided on a targeted new issue of 20 million shares, which will bring the company 7.6 million kronor before deductions...

August 27 Finanzen.ch

Modus Therapeutics released figures for the previous quarter

Modus Therapeutics presented the figures for the most recent quarter at the financial conference held on August 26, 2026, which ended on June 30, 2026...

Never miss news about Modus

Track Modus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.